All BPC-157 peptides dispensed by our clinic are produced in FDA-monitored facilities and intended for physician-supervised research and therapeutic use only not for purchase from online research sources, which often contain impure or mislabeled products
Clinical insight: European Journal of Pharmacology (2023) found BPC-157 significantly reduced tissue necrosis and vascular damage in ischemic injury models
We particularly look at these peptides for inflammatory conditions: BPC-157 has been studied for joint discomfort, digestive issues, and stubborn injuries
Each produces a different concentration and a different syringe draw volume for the same target dose
Common side effects are mild: brief soreness or a small bruise at the injection site, slight lightheadedness, or a mild headache
Reconstitution reference U100 units to draw for each common Semaglutide dose, by vial size, reconstituted with 2 mL of bacteriostatic water